Mott David M is a director of Mersana Therapeutics Inc.
Person profile
Roles
Address
Baltimore, Maryland
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Mersana Therapeutics, Inc.
4 Jan 24
4
Mersana Therapeutics, Inc.
4 Oct 23
4
Mersana Therapeutics, Inc.
6 Jul 23
4
Adaptimmune Therapeutics PLC
3 Jul 23
4
ARDELYX, INC.
16 Jun 23
4
NOVAVAX INC
13 Jun 23
4
Mersana Therapeutics, Inc.
12 Jun 23
4
Mersana Therapeutics, Inc.
5 Apr 23
4
ARDELYX, INC.
17 Nov 22
4
Epizyme, Inc.
16 Aug 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jan 24 | MRSN Mersana Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 8,810 | 0.00 | 588,694 |
2 Oct 23 | MRSN Mersana Therapeutics | Common Stock | Grant | Acquire A | No | No | 0 | 15,873 | 0.00 | 579,884 |
3 Jul 23 | ADAP Adaptimmune Therapeutics | Option to purchase Ordinary Shares Ordinary Shares | Grant | Acquire A | No | No | 0.16 | 1,462,927 | 234.07 k | 1,462,927 |
15 Jun 23 | ARDX Ardelyx | Common Stock | Grant | Acquire A | No | No | 0 | 25,510 | 0.00 | 1,192,275 |
15 Jun 23 | ARDX Ardelyx | Stock Option Common Stock | Grant | Acquire A | No | No | 3.92 | 49,237 | 193.01 k | 49,237 |
12 Jun 23 | NVAX Novavax | RSU Common Stock | Grant | Acquire A | No | No | 0 | 6,670 | 0.00 | 6,670 |
12 Jun 23 | NVAX Novavax | Stock Option Common Stock | Grant | Acquire A | No | No | 7.78 | 7,710 | 59.98 k | 7,710 |
10 Jun 23 | NVAX Novavax | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,100 | 0.00 | 43,800 |
10 Jun 23 | NVAX Novavax | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,100 | 0.00 | 0 |